Soiken Holdings Inc. (TYO:2385)
224.00
-1.00 (-0.44%)
Aug 27, 2026, 1:28 PM JST
Soiken Holdings Revenue
In the fiscal year ending June 30, 2026, Soiken Holdings had annual revenue of 3.87B JPY, down -20.15%. Soiken Holdings had revenue of 635.00M in the quarter ending June 30, 2026, a decrease of -45.63%.
Revenue
3.87B
Revenue Growth
-20.15%
P/S Ratio
1.52
Revenue / Employee
47.79M
Employees
49
Market Cap
5.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.87B | -977.00M | -20.15% |
| Jun 30, 2025 | 4.85B | -310.00M | -6.01% |
| Jun 30, 2024 | 5.16B | -2.92B | -36.16% |
| Jun 30, 2023 | 8.08B | -1.27B | -13.57% |
| Jun 30, 2022 | 9.35B | 405.00M | 4.53% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CellSource | 3.67B |
| PRISM BioLab Co.,LTD | 737.27M |
| Chiome Bioscience | 615.15M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| ADR Biomedical Holdings | 101.00M |
| Ribomic | 7.50M |
| Noile-Immune Biotech | 1.00M |